Literature DB >> 8647777

Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.

M A Visalli1, M R Jacobs, P C Appelbaum.   

Abstract

Activity of CP 99,219 (trovafloxacin), clinafloxacin, ciprofloxacin, sparfloxacin, lomefloxacin and cefuroxime against 4 penicillin-susceptible, 2 penicillin-intermediate and 4 penicillin-resistant pneumococci was tested by MIC and time-kill methodology. Bacteriostatic values for all three groups did not differ significantly with all compounds tested except cefuroxime, and were lowest for trovafloxacin and clinafloxacin, followed by sparfloxacin, ciprofloxacin and lomefloxacin; cefuroxime yielded values which increased in line with those of penicillin G. The test compounds were bactericidal (i.e. they reduced original counts by > or = 3 log10 cfu/mL at one dilution above bacteriostatic levels) in most cases, though some strains showed slightly greater discrepancies between bacteriostatic and bactericidal levels of all compounds tested. Trovafloxacin, clinafloxacin and sparfloxacin yielded MIC and time-kill results which point to possible efficacy in treatment of penicillin-susceptible and -resistant pneumococcal infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647777     DOI: 10.1093/jac/37.1.77

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors:  F Fitoussi; C Doit; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  J P Bédos; V Rieux; J Bauchet; M Muffat-Joly; C Carbon; E Azoulay-Dupuis
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  The management gram-negative bacterial haematogenous vertebral osteomyelitis: a case series of diagnosis, treatment and therapeutic outcomes.

Authors:  Simon Matthew Graham; Adelle Fishlock; Peter Millner; Jonathan Sandoe
Journal:  Eur Spine J       Date:  2013-04-01       Impact factor: 3.134

4.  Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.

Authors:  J S Bradley; G L Kearns; M D Reed; E V Capparelli; J Vincent
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.

Authors:  T D Gootz; R P Zaniewski; S L Haskell; F S Kaczmarek; A E Maurice
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.

Authors:  K S Thomson; S A Chartrand; C C Sanders; S L Block
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.

Authors:  L E Stearne; C Kooi; W H Goessens; I A Bakker-Woudenberg; I C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

8.  Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.

Authors:  A J Fischman; J W Babich; A A Bonab; N M Alpert; J Vincent; R J Callahan; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Authors:  B Ji; N Lounis; C Maslo; C Truffot-Pernot; P Bonnafous; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.